Benjamin Bailly completed most of his undergraduate studies in biochemical engineering and biotechnologies at the Université Lyon 1, in France. In 2010, he joined the team of Prof. Mark von Itzstein at the Institute for Glycomics in Australia, where he worked on the expression of the human parainfluenza type 3 HN protein for target-based drug design. From there, he set out to do a PhD in collaboration with Prof. Ralf Altmeyer at the Institut Pasteur of Shanghai, where he ended up doing all of his doctoral work.
During his PhD, Dr Bailly made significant advances in the field of anti-paramyxovirus research, from the target-based and phenotypic discovery of candidates against parainfluenza virus and respiratory syncytial virus, to the characterisation of their mode of action. Benjamin is now back to the Institute for Glycomics where he is working on the discovery of new-generation influenza virus sialidase inhibitors, glycan-based strategies for the inhibition of enterovirus 71 infection, as well as the characterisation of the enterovirus-host glycointeractome and its role in cell tropism. Dr Bailly was awarded a Griffith University New Researcher grant in 2016 and an Institute for Glycomics Early Career Researcher Excellence Award in 2017 in recognition of his achievements.
Abstracts this author is presenting: